[go: up one dir, main page]

GR3022838T3 - Peptide-based inhibitors of hiv replication - Google Patents

Peptide-based inhibitors of hiv replication

Info

Publication number
GR3022838T3
GR3022838T3 GR970400513T GR970400513T GR3022838T3 GR 3022838 T3 GR3022838 T3 GR 3022838T3 GR 970400513 T GR970400513 T GR 970400513T GR 970400513 T GR970400513 T GR 970400513T GR 3022838 T3 GR3022838 T3 GR 3022838T3
Authority
GR
Greece
Prior art keywords
hiv replication
peptide
based inhibitors
oligopeptide
inhibition
Prior art date
Application number
GR970400513T
Other languages
English (en)
Inventor
Martin Sumner-Smith
Richard W Barnett
Lorne S Reid
Nahum Sonenberg
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Publication of GR3022838T3 publication Critical patent/GR3022838T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR970400513T 1990-10-24 1997-03-17 Peptide-based inhibitors of hiv replication GR3022838T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60295390A 1990-10-24 1990-10-24
PCT/CA1991/000378 WO1992007871A1 (en) 1990-10-24 1991-10-23 Peptide-based inhibitors of hiv replication

Publications (1)

Publication Number Publication Date
GR3022838T3 true GR3022838T3 (en) 1997-06-30

Family

ID=24413440

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400513T GR3022838T3 (en) 1990-10-24 1997-03-17 Peptide-based inhibitors of hiv replication

Country Status (11)

Country Link
EP (1) EP0554284B1 (el)
JP (1) JPH06501938A (el)
AT (1) ATE146483T1 (el)
AU (1) AU660947B2 (el)
CA (1) CA2092075A1 (el)
DE (1) DE69123754T2 (el)
DK (1) DK0554284T3 (el)
ES (1) ES2095959T3 (el)
FI (1) FI931801L (el)
GR (1) GR3022838T3 (el)
WO (1) WO1992007871A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
AU4037793A (en) * 1992-04-23 1993-11-29 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2152387C (en) * 1992-12-22 1998-10-27 Michael Twist (Deceased) Synergistic anti-viral compositions
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU685862B2 (en) * 1993-10-22 1998-01-29 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
US5627194A (en) * 1993-11-17 1997-05-06 Allelix Biopharmaceuticals Inc. Anti-viral guanidino-substituted compounds
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2003507438A (ja) 1999-08-24 2003-02-25 セルゲイト, インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
CA2458677A1 (en) * 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
ATE461708T1 (de) * 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
BRPI0608091A2 (pt) 2005-03-03 2009-11-10 Revance Therapeutics Inc composições e processos para aplicação tópica e distribuição transdérmica de um oligopeptìdeo
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
CA2629499A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
CA2764164A1 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
MX2015002465A (es) 2012-08-31 2015-11-06 Univ North Carolina Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
EP0554284B1 (en) 1996-12-18
FI931801A7 (fi) 1993-04-21
WO1992007871A1 (en) 1992-05-14
AU660947B2 (en) 1995-07-13
FI931801A0 (fi) 1993-04-21
DE69123754T2 (de) 1997-04-03
JPH06501938A (ja) 1994-03-03
ATE146483T1 (de) 1997-01-15
ES2095959T3 (es) 1997-03-01
CA2092075A1 (en) 1992-04-25
FI931801L (fi) 1993-04-21
AU8725991A (en) 1992-05-26
DE69123754D1 (de) 1997-01-30
DK0554284T3 (da) 1997-01-06
EP0554284A1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
GR3022838T3 (en) Peptide-based inhibitors of hiv replication
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR0115447A (pt) Inibidores de tripeptìdeo de hepatite c
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
MX9303694A (es) Peptidos.
ATE169822T1 (de) Behandlung von herpesvirus infektion
NZ215096A (en) Renin inhibiting peptide derivatives, pepstatin analogues
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
DE69330268D1 (de) Hämoregulierende peptide
KR920000790A (ko) Hiv프로테아제 억제제 및 이의 제조방법
AP2002002584A0 (en) Protease Inhibitors And Thier Pharmaceutical Uses.
RU94014631A (ru) Производные 4-хиномиодигидропиридина, смесь их изомеров или отдельные изомеры и их соли
WO1999058638A3 (en) Sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
ATE189460T1 (de) Gegen protozoen wirksamezyklische tetrapeptide
NO931503L (no) Peptidbaserte inhibitorer av hiv-replikasjon
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ES2073286T3 (es) Productos cosmeticos estables.
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
SE9702242D0 (sv) Vaccine compositions V
DK0783319T3 (da) Muramylpeptid-sammensætninger til inhibering af HIV replikation
KR970704441A (ko) 사람 면역결핍증 바이러스 프로테아제 억제제 배합물(HIV Protease inhibitor combination)
EP0355409A3 (en) Use of prolylendopeptidase inhibitors in the treatment of aids